Apollomics (APLM) Insider Hong-Jung Chen Sells 500 Shares

Hong-Jung Chen Executes Stock Sale at Apollomics

Hong-Jung Chen sold 500 shares of Apollomics, Inc. (NasdaqCM: APLM) on June 15, 2026. This transaction was part of a cluster of filings submitted by company insiders on the exact same date, capturing attention across the clinical-stage biotech firm. While 500 shares represents a modest individual transaction, it arrived alongside several other trades from company leadership.

A Busy Day of Insider Activity

The June 15, 2026 filings revealed heavy movement among key personnel at Apollomics, Inc. Chief Financial Officer Lin Peter Kuan-How made a much larger move, selling 10,000 shares on the same day. Other insiders were also active, with Yi-An Chu selling multiple blocks of 500 shares, while Hsien-Shu Tsai and Chen-Huan Jan each picked up 500 shares of the stock.

Apollomics Stock Performance and Trading Range

Shares of Apollomics, Inc. changed hands around $13.85 recently. The stock has experienced a wide trading span over the past year, recording a 52-week low of $10.01 and a high of $42.12. The current price sits below its 50-day moving average of $21.45, though it remains near its 200-day moving average of $18.40.

Inside Apollomics, Inc.

Based in Foster City, California, Apollomics, Inc. works on oncology treatments and cancer therapies designed to target specific molecular pathways. The clinical-stage biopharmaceutical firm develops product candidates such as Vebreltinib for non-small cell lung cancer alongside various immuno-oncology therapies.

What to Watch at APLM

Investors tracking Apollomics, Inc. will want to watch for subsequent Form 4 filings to see if insiders continue adjusting their positions following this flurry of activity. Future clinical updates on the company's oncology pipeline will also drive market interest. As always, insider transactions reflect individual financial choices rather than broad buy or sell signals for the wider market.